Exagen

Canaccord Genuity Acted as the Sole Bookrunner to Exagen Inc. on its $20.2 Million Public Offering

Canaccord Genuity is pleased to announce that on May 9, 2025, it completed a public offering of common stock for Exagen Inc. (NASDAQ: XGN) (the “Company”). The offering comprised of 3,852,500 shares of common stock, including the exercise in full of the underwriter’s option to purchase additional shares, at a public offering price of $5.25 per share, resulting in gross proceeds of $20.2 million. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes and may also use a portion of the net proceeds from the offering to acquire, in-license or invest in products, technologies or businesses that complement the business. 

Canaccord Genuity acted as the sole bookrunner for the offering.
    
Exagen Inc. is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The Company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE®-branded tests for disease diagnosis, prognosis and monitoring. With a focus on research, innovation, education and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.